BIO MEDICAL AUTOMATION INC, 10KSB, 2000-03-23

BIO MEDICAL AUTOMATION INC
10KSB, 2000-03-23
COMPUTER PERIPHERAL EQUIPMENT, NEC

Previous: GE LIFE & ANNUITY ASSURANCE CO III, 24F-2NT, 2000-03-23

Next: FRANKLIN CAPITAL CORP, 10-K405, 2000-03-23

<PAGE> 1

FORM 10-KSB
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1999
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .
---------------- ------------------

Commission File Number 0-16335

BIO-MEDICAL AUTOMATION, INC.
(Name of Small Business Issuer as Specified in its Charter)

Colorado 84-0922701
(State or other juris- (IRS Employer
diction of incorpora- Identification No.)
tion or organization)

303 East 17th Avenue
Suite 780
Denver, Colorado 80203
(Address of Principal Executive Offices)

Issuer's telephone number, including area code: (303) 832-8520

Securities registered under Section 12(g) of the Exchange Act:
$0.10 Par Value Common Stock
(Title of Class)

Indicate by check mark whether the Issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months and, (2) has been subject to such filing requirements
for the past 90 days. YES [X] NO [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein and will not be contained, to the best
of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. [ ]

Revenues for fiscal year ended December 31, 1999, were $13,132 from continuing
operations and approximately $525,000 from discontinued operations. The
aggregate market value of the Registrant's voting stock held, as of March 15,
2000, by nonaffiliates of the Registrant was $363,101

As of March 15, 2000, Registrant had 643,128 shares of its $0.10 par value
common stock outstanding.

Total Pages: 30
Exhibit Index at Page: 29

<PAGE> 2

PART I

ITEM 1. BUSINESS.

(a) BUSINESS DEVELOPMENT. Bio-Medical Automation, Inc. ("BMA" or the
"Company") was incorporated as a Colorado Corporation on October 13, 1983 under
the name `OZO Diversified Automation, Inc.' ("OZO"). The Company changed its
name to BMA in March 1999, following shareholder approval of the name change in
connection with the sale of substantially all of the Company's assets to JOT
Automation, Inc. (referred to herein as the "JOT Transaction" and "JOT",
respectively).

Since its formation, and until the completion of the JOT
Transaction, the Company had been engaged in the design and manufacture of
robotic workstations for the electronics industry. The initial products offered
by OZO included small-scale CNC (Computer Numerically Controlled) drilling
machines that were, and are, commonly used in the fabrication of prototype
printed circuit boards. As of the late 1980s, the Company diversified its
product line to include routing and depaneling workstations. Until the
completion of the JOT Transaction, the core business of the Company was the
development, manufacturing, and sale of routing and depaneling robotic
workstations for use in the electronics industry (referred to herein as the
"routing and depaneling business"). The JOT Transaction resulted in the sale of
the routing and depaneling business to JOT as described below.

In recent years the Company had also developed a prototype
micro-robotic device (the "prototype device") to manipulate organic tissues on
an extremely small scale. Prior to the JOT Transaction the Company had not been
able to complete the development of this prototype device because it needed to
conserve its resources for use in the routing and depaneling business. The sale
of the routing and depaneling business to JOT was intended to allow the Company
to focus its efforts on the completion of the development of this prototype
device. Because of various developments, including primarily the unavailability
of the developer of the prototype device, the Company was not able to proceed as
planned. As of March 25, 2000, a long-time shareholder of the Company had chosen
to acquire sufficient additional shares of the Company from other shareholders
in order to acquire a controlling interest. New directors and management of the
Company have been appointed effective March 25, 2000, and new management will
choose the direction of the Company. It is believed that new management, after
it is appointed, will consider as yet unspecified business combinations and
financing opportunities, in order to generate value for the shareholders
although there can be no assurance that the Company will be able to complete
either. This shareholder's intentions for the Company and the prototype device
are unknown to current management at this time.

1
<PAGE> 3

RISK FACTORS

AS NOTED ELSEWHERE HEREIN, THE FUTURE CONDUCT OF THE BUSINESS OF
THE COMPANY AND ITS RESPONSE TO ISSUES RAISED BY THIRD PARTIES ARE DEPENDENT
UPON A NUMBER OF FACTORS. CERTAIN STATEMENTS CONTAINED IN THIS REPORT USING THE
TERMS "MAY," "EXPECTS TO," AND OTHER TERMS DENOTING FUTURE POSSIBILITIES, ARE
FORWARD-LOOKING STATEMENTS. THE ACCURACY OF THESE STATEMENTS CANNOT BE
GUARANTEED AS THEY ARE SUBJECT TO A VARIETY OF RISKS WHICH ARE BEYOND THE
COMPANY'S ABILITY TO PREDICT OR CONTROL, AND WHICH MAY CAUSE ACTUAL RESULTS TO
DIFFER MATERIALLY FROM THE PROJECTIONS OR ESTIMATES CONTAINED HEREIN. THESE
RISKS INCLUDE, BUT ARE NOT LIMITED TO THE FOLLOWING RISKS:

o Risks associated with the investment in a company with no
historical profitability.

o Risks associated with the investment in a company with no future
business plan or plan of operations.

o Risks associated with the investment in a company with no
management personnel.

o Risks associated with the investment in a company with no assets
other than cash and an unproven, not fully developed prototype
device.

o Risks associated with the investment in a company that is subject
to a change in management control.

IT IS IMPORTANT THAT EACH PERSON REVIEWING THIS ANNUAL REPORT
UNDERSTANDS THE SIGNIFICANT RISKS ATTENDANT TO THE OPERATIONS OF THE COMPANY.
THE COMPANY DISCLAIMS ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENT
MADE HEREIN EXCEPT TO THE EXTENT REQUIRED TO DO SO IN FURTHER REPORTS TO BE
FILED PURSUANT TO THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

2
<PAGE> 4

(b) BUSINESS OF ISSUER. As noted above, as a result of the completion
of the JOT Transaction, the Company is no longer participating in its historical
business activities. Those historical activities are now considered to be
"discontinued operations" for financial statement purposes. As a result, this
section describes BMA's business "prior to the completion of the JOT
Transaction" and its "plan of operations." The Company engaged in this business
from January 1, 1999, through March 9, 1999. After March 9, 1999, the Company
has engaged in no significant business operations. According to the Company's
original plan of operations as disclosed in prior filings, research and
development was to have been devoted to developing the technology and building
the prototype device as described. General and administrative expenditures were
and have been directed to maintaining the Company's status as a public company,
including (without limitation) filing reports with the Securities and Exchange
Commission.

Initially the Company believed that the net proceeds from the JOT
Transaction would enable the Company to continue its research and development
activities for the technology necessary to complete the development of the
prototype device, and to pursue the patent application for the prototype device.
The net proceeds were expected to be sufficient to allow the Company to complete
the development of a functional prototype device (although there was and could
be no assurance that these efforts would have been successful). If successful,
the Company would have also identified estimated manufacturing and production
costs for the prototype device. At that time, the Company would likely not have
had sufficient capital to produce or market the prototype device, and would have
either begun an effort to raise additional capital and begun building and
distributing the technology internally, or would have pursued an outside
business partnership with that expertise.

The prototype device had been under development by an officer of
the Company, Mr. David W. Orthman, prior to the completion of the JOT
Transaction and the Company expected that this development would continue after
the JOT Transaction was completed. As discussed in other reports filed by the
Company, a significant amount of work is required within certain specialized
disciplines to complete the development of the prototype device. Mr. Orthman has
been unable to continue to work on the prototype device because of a disability
that has surfaced since the completion of the JOT Transaction. As previously
reported, Mr. Orthman had informed the Company that doctors have advised him
that it would be until Spring 2000 at the earliest before he would be able to
devote any significant efforts to the technology or the prototype device.

As described in other reports filed by the Company, because of the
uniqueness of the technology and other factors, there can be no assurance that
the Company will be able to successfully develop the prototype even if Mr.
Orthman is able to devote sufficient time to the project. Without the dedicated
efforts of Mr. Orthman, it is unlikely that the Company will be able to complete
the prototype device utilizing the technology. As a result, the Company has
obtained an independent third party evaluation of the technology. The Company
considers the results of this study to be positive and a ratification of the
Company's decision to pursue the technology initially following the completion
of the JOT Transaction. However, because of Mr. Orthman's continued
unavailability, depleting working capital, and the passage of time, the Company
has reconsidered this decision and the Board of Directors determined to consider
alternatives. Mr. Orthman is under no employment agreement with the Company, and
has no obligation to provide services to the Company at this time.

3
<PAGE> 5

Even if the Company were able to complete the prototype device with
the limited resources available following the completion of the JOT Transaction,
there was and continues to be no assurance that it will be able to generate
revenues for the Company. Unless the Company is able to generate revenues from
(or after) the development of the prototype device and related technology, the
Company will be unable to continue as a going concern.

Plan of Operations

Effective March 25, 2000, a shareholder, Steven Bronson, who has
acquired control of the Company, has advised current management that he
anticipates that the Board will consider various alternative courses of action
for the Company. These courses, if selected, may or may not require shareholder
approval. There can be no assurance, however, that any of the courses selected
may be successful. The courses management may consider could include, but are
not limited to, any of the several alternatives, or combinations thereof,
briefly identified as follows, and described in more detail below:

1. Business Combinations.

2. Continuation of the Company as a Going Concern.

3. Dissolution and Liquidation.

4. Sale or License of the Technology.

Neither the current Board of Directors nor Mr. Bronson has made any
determination as to which, if any of the foregoing alternatives, it may
recommend to the shareholders of the Company. Where shareholder approval is
required, any such recommendation will be in the form of a proxy statement
meeting the requirements of Schedule 14A of the Securities Exchange Act of 1934,
as amended.

Business Combinations. It is possible that the Company may attempt
to implement a business plan to seek, investigate, and, if warranted, to acquire
an interest in a business opportunity which management believes may provide a
return to the Company and its shareholders. The Company may do so through a
merger, a reverse merger, an acquisition of assets, or other method. The Company
may attempt to do so using its working capital or its unissued common stock
instead of cash or debt; any issuance of common stock or other equity interest
would dilute the ownership percentage of the Company's existing shareholders.

The Company has not identified a business opportunity for
acquisition. It is expected to seek out developing companies to allow the
Company to expand into new products or markets, or to develop a new product or
service. Established businesses which may be experiencing financial or operating
difficulties and would be in need of the additional capital and management
expertise the Company could provide also will be investigated. In some
instances, a business opportunity may involve the acquisition of or merger with
a corporation which does not need substantial additional cash but which desires
to have a public trading market for its securities.

4
<PAGE> 6

The Company anticipates that the selection of a business
opportunity will be a complex process and will involve a number of risks,
because potentially available business opportunities may occur in many different
industries and may be in various stages of development. Due in part to depressed
economic conditions in a number of geographic areas, rapid technological
advances being made in some industries and shortages of available capital,
management believes that there are numerous firms seeking either the limited
additional capital which the Company will have or the benefits of a publicly
traded corporation, or both. The perceived benefits of a publicly traded
corporation may include facilitating or improving the terms upon which
additional equity financing may be sought, providing liquidity for estate
planning needs of principle shareholders, creating a means for providing
incentive stock options or similar benefits to key employees, providing
liquidity for all shareholders and other factors.

In seeking business opportunities, management's decision will
likely be based upon the objective of seeking long-term capital appreciation in
real value of the Company's investment. Current income will be only a minor
factor in such decisions.

It is anticipated that the Company will essentially be limited to
one business venture in the foreseeable future, due to the Company's limited
financing. This lack of diversification will not permit the Company to offset
potential losses from one business opportunity against profits from another, and
should be considered an adverse factor affecting any decision to purchase the
Company's securities.

In some cases, management of the Company will have the authority to
effect acquisitions without submitting the proposal to the shareholders for
their consideration. In some instances, however, the proposed participation in a
business opportunity may be submitted to the shareholders for their
consideration, either voluntarily by the Board of Directors to seek the
shareholders' advice and consent, or because of a requirement of state law to do
so. There can be no assurance that the Company will be able to complete any such
acquisition.

The Company does not intend to engage in any action that would lead
to its classification as an "investment company" as that term is defined in the
1940 Act. An investment company is generally a company that is engaged in the
business of investing, holding, reinvesting, or trading of investment
securities. Investment securities are defined by the 1940 Act to include all
securities except United States government obligations, certain other securities
and cash where the Company has less than a 50% interest in the issuer. The
Company does not intend nor does it have authority to engage in the business of
investing, holding, reinvesting, or trading of investment securities.

Continuation of the Company as a Going Concern. Pursuant to this
alternative, the Company, through its elected Board of Directors and management,
would pursue new or existing business opportunities and consider various
possibilities of reorganization with the intention of allowing the Company to
engage in active business operations. Although there can be no guarantee of
success, this may or may not include an attempt to commercialize the Company's
prototype device.

5
<PAGE> 7

Dissolution and Liquidation. At the present time, neither current
management nor, to the knowledge of current management, the shareholder who
acquired control, have any intention to liquidate the Company. That is an
alternative that may be considered at some point, however. To the extent the
Board of Directors recommends liquidation to the shareholders, it will do so in
accordance with the applicable requirements of Colorado corporation law and the
requirements of the Securities Exchange Act of 1934.

Sale or License of the Technology. As noted above, management has
received information that the Technology, although in preliminary stages of
development, may have some value, although the value to third parties is likely
to be limited. If an appropriate opportunity arises, management will consider
possibilities for the sale or license of the Technology.

Prior to the Completion of the JOT Transaction

BMA, prior to the completion of the JOT Transaction on March 9,
1999, manufactured and marketed robotic workstations, which are used by the
electronics industry for the depaneling, routing, and drilling of printed
circuit boards. In addition to furnishing the base workstations, the Company
also provided sophisticated motion control software that is used to operate the
machines for specific applications.

Prior to the completion of the JOT Transaction, the Company's
products were defined by a two-tier offering of equipment and accessories:

o The upper tier (or premium line) which represented BMA's core
business, was comprised of the Company's high-end servomotor
robotic systems, including the Model 18HS standalone router, and
the Model 16SI fully-automated, inline system, which were marketed
under the trade names PanelMASTER 18HS and PanelROUTER 16SI,
respectively.

o The lower tier offering was comprised of the Company's
stepper-motor systems, which included the Model 18 and Model 24
multipurpose machines, which were distributed under the
PanelMASTER, FixtureMASTER, EtchMASTER, and LabMASTER product
designations.

o On a limited basis, the Company also supplied a dual-spindle
drilling platform (Model 2-24), as well as a large format multi-use
machine (Model 32), both of which are dedicated to a very narrow
market segment. The Model 2-24 and Model 32 machines were available
only on a special order basis.

The majority of the Company's 1999 revenue derived from the sale of
its premium line of depaneling equipment. As a result of the completion of the
JOT Transaction, however, all of these products are now offered by JOT.

6
<PAGE> 8

Prior to the completion of the JOT Transaction, the Company had
competed in four distinct segments of the capital equipment market:

o depaneling equipment;

o low-to-medium volume bare board drilling and routing equipment;

o test fixture drilling and routing equipment; and

o prototyping equipment.

Nationally and internationally, there were numerous competitors who
manufacture depaneling, routing and drilling equipment. In many cases, the
competitors identified operate divisions of companies larger than BMA and
generate revenues from various products. Prior to the completion of the JOT
Transaction, the Company believed that under historical market conditions it
could compete favorably in the depaneling equipment market. However, the Company
had not been successful in the market conditions which evolved during the second
half of 1997, and persisted throughout 1998, and this was a primary reason for
the proposal (approved by the shareholders) to sell the depaneling and routing
business to JOT. The Company believed that its ability to continue to compete
was significantly hampered by being a standalone depaneling equipment
manufacture in a market that no longer recognized best-of-breed,
single-equipment manufacturers. By comparison, JOT has an integrated line of
products, which can utilize the Company's former products in providing
integrated solutions to its customers.

Prior to the completion of the JOT Transaction, the Company
procured parts and raw materials from a broad base of suppliers, and did not
rely on one, or a few, major vendors for critical components. Most materials
purchased by the Company were off-the-shelf items.

Prior to the completion of the JOT Transaction, the Company was not
dependent on one, or a few, major customers.

Prior to the completion of the JOT Transaction, the Company had not
sought patent protection for the hardware it developed, but considered certain
aspects to be proprietary to the Company and were protected as trade secrets.
The Company had made only a limited search of existing patents to determine the
extent to which such proprietary protection may have been available or whether
the Company's products infringed on patents held by others. A claim against the
Company for possible infringement of a patent was made in 1994, and the Company
has executed a License Agreement with the unaffiliated claimant. Royalties were
paid in 1998 and 1999 under this License Agreement. The Company is unaware of
any other claims or proprietary rights of others on which the Company's products
may be deemed to infringe.

The Company had acquired copyright protection for the Company's
proprietary software, which was a key component of the operation of the
Company's workstation systems. Specifically, copyright protection for the
Company's proprietary stepper motor software was acquired on May 26, 1988. The
Company acquired copyright protection for the Company's servomotor software on
October 27, 1994. Subsequently, as the software has been improved, additional
copyright protection has been obtained.

7
<PAGE> 9

As a result of the completion of the JOT Transaction, the Company
assigned its technology, copyrights, and trade secrets to JOT, however BMA
licensed the right to use a portion of the technology to integrate into, and to
complete the development of, its prototype device.

Prior to the completion of the JOT Transaction, the Company had
expended approximately $0 and $167,807, for research and development in the
fiscal years ending December 31, 1999, and December 31, 1998, respectively.

The Company does not receive funding from other parties to conduct
research and development, except in specific cases where U.S. government NSF or
ARPA grants may be awarded. The Company received no grants in 1999 or 1998.

Summary of JOT Transaction

The Company completed the JOT Transaction pursuant to an Asset
Purchase Agreement (the "Agreement"), dated November 4, 1998 (and amended
December 15, 1998), with JOT Automation, Inc. ("JOT"), a wholly-owned Texas
subsidiary of JOT Automation Group Plc., a Finnish corporation which has its
common stock registered on the Helsinki Stock Exchange, on March 9, 1999. JOT is
engaged in the business of production automation and robotics for use within the
electronics industry. The Company sold to JOT all of its assets relating to its
depaneling and routing business in exchange for $920,000 and the assumption of
the operating liabilities related to the Company's business assets (the "JOT
Transaction"). BMA used a portion of the gross proceeds to reimburse JOT for
expenses incurred by BMA in maintaining the assets not transferred to JOT, to
pay certain expenses of the JOT Transaction, and to repay indebtedness to
related parties and to third parties, as follows:

<TABLE>

<S> <C>
Purchase Price $ 920,000
Indebtedness payable 179,830
Sales and use taxes (estimate) 20,000
Finder's fee (Capitalink) 40,366
Recoupment expenses paid to JOT 80,000
------------
Net proceeds remaining (estimated) $ 599,804
============
</TABLE>

As a result of the JOT Transaction, JOT acquired approximately 99%
of the Company's total assets, which had generated 100% of the Company's
revenues and were responsible for approximately 99% of the Company's expenses.

JOT also acquired the rights to the OZO name and trademark,
copyrighted software, and the Company's customer lists. Virtually all of the
Company's employees became JOT employees, and the Company's former production
facility in Denver has continued to operate for JOT in much the same manner as
it did before the JOT Transaction.

8
<PAGE> 10

BMA retained certain assets, which included the net cash proceeds
of the JOT Transaction and a new technology currently under development. The
prototype device described above is one aspect of this new technology. Because
the new technology represents a significant departure from the current product
line, it is unlikely any of the Company's former customers in the depaneling and
routing business will continue as customers after (if ever) the new technology
is commercially available.

As a part of the JOT Transaction, JOT licensed certain technologies
back to BMA. This will allow the Company to continue to use copyrighted motion
control and automation software in certain fields of use. These fields of use
include, among other things, the manipulation of biological systems in order to
accomplish a wide range of research, medical and commercial objectives. This is
a fully paid, non-revocable, transferable, royalty-free license in perpetuity
offered by JOT to the Company.

General Information

Raw Materials. Prior to the completion of the JOT Transaction, the
Company procured parts and raw materials from a broad base of suppliers, and
does not rely on one, or a few, major vendors for critical components. Most
materials purchased by the Company are off-the-shelf items. The Company believes
that this situation will continue in the future.

Customer Dependence. The Company has not in the past been dependent
on one, or a few, major customers. Until the Company completes the development
of the prototype device and related technology, the Company will have no
product(s) to sell. In fact, the Company had no customers after the JOT
transaction neither in 1999 nor through March 15, 2000.

Government Approval. The Company has not been, and does not expect
to be, subject to any government approval for its product(s).

Government Regulation. The Company has no knowledge of impending
government regulation on its business.

Environmental Regulation. Since its inception, the Company has not
made any material capital expenditures for environmental control facilities and
the Company does not expect to make any such expenditures during the current or
forthcoming fiscal year. The Company believes that it is in full compliance with
all federal, state, and local environmental regulations.

Employees. As of December 31, 1999, the Company had no full-time
employees and one contract employee. As of March 25, 2000, the Company had one
contract employee which tendered his resignation.

9
<PAGE> 11

ITEM 2. PROPERTIES

Prior to the completion of the JOT Transaction, the Company's
combined office and production space totaled approximately 9,040 square feet as
to which the Company had a monthly rental obligation of approximately $4,300
through the expiration of the lease on February 29, 2000.

As a result of the completion of the JOT Transaction, JOT assumed
all liabilities under that lease. Currently the Company subleases one office
located in Denver, Colorado, for $400 per month. The Company maintains its
records in that office. The lease is month-to-month.

ITEM 3. LEGAL PROCEEDINGS

There are no pending legal proceedings to which the Company is a
party or of which any of its property is the subject as of the date of this
report and there were no such proceedings during the fiscal years ended December
31, 1999, or December 31, 1998, or subsequently.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matter was submitted during the fourth quarter of the fiscal
year 1999 to a vote of the Company's security holders. However two proposals
were submitted to shareholders for their approval in March 1999:

o A proposal to approve the sale of substantially all of the assets
of the Company and change the name of the Company to become
effective at the time of the completion of the sale of assets; and

o A proposal to adopt a new Article IX to the Company's Restated
Articles of Incorporation, as amended, to provide for the
limitation of certain liabilities of the Company's directors to the
Company and its shareholders as permitted under Section
7-108-402(1) of the Colorado Business Corporation Act.

10
<PAGE> 12

The shareholders approved both proposals. The shareholders' meeting
was adjourned until April 22, 1999, at which time a third proposal was
considered. That proposal was:

o A proposal to amend Article VI of the Company's Restated Articles
of Incorporation, as amended, to reduce the vote required by
shareholders to approve asset dispositions, mergers, consolidations
or exchanges, and any other matter which would require an amendment
to the Company's Restated Articles of Incorporation, as amended,
from two-thirds to a majority.

The shareholders approved this proposal as well. No other matters were
submitted to the Company's security holders in 1999, or subsequently.

11
<PAGE> 13

PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

(a) MARKET INFORMATION. The Company's common stock is quoted on the OTC
(Over-The-Counter) Bulletin Board and traded under the symbol ("BMAI"). Prior to
the completion of the JOT Transaction, on March 9, 1999, the Company traded
under the symbol ("OZOA"). The following table shows the range of high and low
closing bid quotations of the Company's common stock as traded in the OTC market
during the last two fiscal years.

COMMON STOCK
------------------------------------------------------------------
Year/Fiscal Period High Bid ($) Low Bid ($)
------------------ ------------ -----------

<S> <C> <C>
1999

First Quarter 1.00 0.50
Second Quarter 0.75 0.5625
Third Quarter 0.6875 0.375
Fourth Quarter 0.75 0.375

1998
First Quarter 0.50 0.50
Second Quarter 0.75 0.50
Third Quarter 0.75 0.75
Fourth Quarter 0.75 0.75
</TABLE>

The above quotations were reported by market makers in the stock
and by the National Quotation Bureau, LLC. The quotations represent prices
between dealers and do not include retail markups, markdowns, or commissions,
and do not necessarily represent prices at which actual transactions were or
could have been effected.

(b) HOLDERS. As of December 31, 1999, the Company had approximately 700
holders of record of its $0.10 par value common stock.

(c) DIVIDENDS. The Company has not declared cash dividends on its
common stock since its inception, and the Company does not anticipate paying any
dividends in the foreseeable future. There are no contractual restrictions on
the Company's ability to pay dividends.

12
<PAGE> 14

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

As a result of the completion of the JOT Transaction, the Company's
historical business, the depaneling and routing business, is considered to be a
"discontinued operation" and, consequently, provides no benefit to persons
seeking to understand the Company's financial condition or results of
operations. Consequently, this management's discussion and analysis is divided
into two parts: Discussion of Continuing Operations and Discussion of
Discontinued Operations. Management believes that the discussion of continuing
operations is more meaningful for an understanding of the Company.

DISCUSSION OF CONTINUING OPERATIONS

RESULTS OF OPERATIONS

After the completion of the JOT Transaction the Company had
essentially no operations in 1999. General and administrative expenses were
almost exclusively incurred to maintain the Company's corporate standing,
approximately $150,200. Expenses related to research and development were
exclusively to maintain the patent application for the prototype device,
approximately $9,700. In addition, the Company's continuing operations in 1999
accounted for approximately $4,000 of interest expense.

Substantially all of the Company's operations prior to the
completion of the JOT Transaction were devoted to the Company's historical
business. Only a small portion of the Company's general and administrative
expense ($60,697 during 1998 or approximately 8%) and of the Company's research
and development expense ($20,596 during 1998, or approximately 12%) were devoted
to the assets the Company retained, relating to the technology for and the
development of the prototype device. In addition, the Company's continuing
operations accounted for approximately $8,130 of interest expense (approximately
15% of total 1998 interest expense).

The Company's continuing operations accounted for no revenues,
except interest income of approximately $13,100 and $0, during the years ended
December 31, 1999, and December 31, 1998, respectively.

The Company recognized a loss of $150,792 for the year ended
December 31, 1999, from continuing operations. As a result of the small amount
of operations devoted to the Company's continuing business, the Company
recognized a net loss of $89,423 from its continuing operations for the year
ended December 31, 1998.

13
<PAGE> 15

The Company believed that this loss from continuing operations will
continue at approximately the same rate, or higher, as during 1999, and
thereafter, until (if ever) the prototype device has been developed and can be
commercialized, or a new plan of operations is implemented by the new
management. From the date of completion of the JOT Transaction, the Company had
expected to spend $600,000 for research and development, and for general and
administrative expenses through approximately June 2000.

According to the Company's original plan of operations as disclosed
in prior filings, research and development was to have been devoted to
developing the technology and building the prototype device as described.
General and administrative expenditures were and have been directed to
maintaining the Company's status as a public company, including (without
limitation) filing reports with the Securities and Exchange Commission.

Although the Company believed that Mr. Orthman, and others under
his direction, would have been able to complete the development of the
technology necessary for the completion of the prototype device with the funds
available, there was and continues to be no assurance that they will be able to
do so. Even if they had been able to complete the prototype device there was and
continues to be no assurance that it will be able to generate revenues for the
Company. Unless the Company is able to generate revenues from (or after) the
development of the prototype device and related technology, or unless the
Company pursues a new plan of operations, the Company will be unable to continue
as a going concern. The Company has no current contract or employment
arrangement with Mr. Orthman.

LIQUIDITY AND FINANCIAL CONDITION.

As of December 31, 1999, the Company has remaining liquidity of
approximately $425,000. The liquidity has been reduced from approximately
$604,000 as of March 9, 1999, the date the JOT Transaction was completed. The
Company had anticipated spending this working capital to pursue the plan of
operations as described above. However, the Company was unable to accomplish
this goal because of Mr. Orthman's unavailability. Unless the Company is able to
generate revenues from (or after) the development of the prototype device and
related technology, or unless the Company is able to acquire a new line of
business on commercially reasonable terms, the Company's liquidity will continue
to be reduced over time.

Consequently, the Company's current financial condition continues
to be entirely dependent on the successful development of the prototype device
and related technology, of which there can be no assurance.

Alternatively, the Company's future financial condition will be
subject to its ability to enter into a business combination with an operating
business on favorable terms that will result in profitability. There can be no
assurance that the Company will be able to do so or, if it is able to do so,
that the transaction will be on favorable terms not resulting in an unreasonable
amount of dilution to the Company's existing shareholders.

14
<PAGE> 16

DISCUSSION OF DISCONTINUED OPERATIONS

RESULTS OF OPERATIONS

For the fiscal year ended December 31, 1999 sales of the Company's
products decreased to $525,000 a 70% decrease from sales of the Company's
products of $1,774,000 recorded for the year ended December 31, 1998. The
decrease in revenues was primarily a result of only nine weeks of sales being
completed prior to the closing of the JOT Transaction in March 1999.

As the Company sold its depaneling and routing business to JOT
Automation, Inc., in the "JOT Transaction" as described elsewhere in this
report, the Company no longer has any interest in continuing revenues from, or
assets associated with, its former depaneling and routing business.

15
<PAGE> 17
ITEM 7. FINANCIAL STATEMENTS

See Financial Statements on pages F-1 through F-17.

16
<PAGE> 18

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
INDEX TO FINANCIAL STATEMENTS

PAGE
<S> <C>

Independent Auditor's Report F-2

Balance Sheet
December 31, 1999 F-3

Statements of Operations
Years Ended December 31, 1998 and 1999 F-4

Statements of Stockholders' (Deficiency) Equity
Years Ended December 31, 1998 and 1999 F-5

Statements of Cash Flows
Years Ended December 31, 1998 and 1999 F-6 -- F-7

Notes to Financial Statements F-8 -- F-17
</TABLE>

F-1
<PAGE> 19

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Stockholders
BIO-MEDICAL AUTOMATION, INC.
(formerly OZO DIVERSIFIED AUTOMATION, INC.)

We have audited the accompanying balance sheet of Bio-Medical Automation, Inc.
(formerly OZO Diversified Automation, Inc.) as of December 31, 1999 and the
related statements of operations, stockholders' (deficiency) equity, and cash
flows for each of the two years in the period ended December 31, 1999. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Bio-Medical Automation, Inc.
(formerly OZO Diversified Automation, Inc.) as of December 31, 1999 and the
results of its operations and its cash flows for each of the two years in the
period ended December 31, 1999 in conformity with generally accepted accounting
principles.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 2, the Company
sold substantively all of the assets and related operations of its operating
segment in 1999. These factors, among others, raise substantial doubt about the
Company's ability to continue as a going concern. Management's plans in regard
to these matters are described in Note 2. The financial statements do not
include any adjustments that might result from the outcome of this uncertainty.

Wheeler Wasoff, P.C.

Denver, Colorado
February 19, 2000

F-2
<PAGE> 20

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
BALANCE SHEET
DECEMBER 31, 1999

ASSETS

<S> <C>
CURRENT ASSET
Cash $ 425,211
-------------

Total Current Asset 425,211

PATENT COSTS 18,724
-------------

$ 443,935
=============

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable and accrued expenses $ 15,393
-------------

Total Current Liabilities 15,393
-------------

STOCKHOLDERS' EQUITY
Preferred stock - $.10 par value
Authorized - 1,000,000 shares
Issued - none- --
Common stock - $.10 par value
Authorized - 5,000,000 shares
Issued and outstanding - 643,128 shares 64,313
Capital in excess of par value 1,312,049
Accumulated (deficit) (947,820)
-------------

428,542
-------------
$ 443,935
=============

</TABLE>

The accompanying notes are an integral part of the financial statements.

F-3
<PAGE> 21

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 1998 AND 1999

1998 1999

<S> <C> <C>
REVENUE
Interest income $ -- $ 13,132
----------- -----------

OPERATING EXPENSES
General and administrative 60,697 150,217
Research and development 20,596 9,653
Interest 8,130 4,014
----------- -----------

(89,423) (163,884)
----------- -----------

(LOSS) FROM CONTINUING OPERATIONS (89,423) (150,752)
----------- -----------

DISCONTINUED OPERATIONS
(Loss) income from discontinued operations (140,022) 33,039
Gain on sale of discontinued segment -- 640,150
----------- -----------
(140,022) 673,189
Income tax expense -- (200,000)
Tax benefit of net operating loss carry forward -- 200,000
----------- -----------

NET (LOSS) INCOME FROM DISCONTINUED OPERATIONS (140,022) 673,189
----------- -----------
NET (LOSS) INCOME $ (229,445) $ 522,437
=========== ===========

(LOSS) INCOME PER COMMON SHARE -
BASIC AND DILUTED
Continuing operations $ (.18) $ (.23)
Discontinued operations (.29) 1.04
----------- -----------

NET (LOSS) INCOME PER COMMON SHARE $ (.47) $ .81
=========== ===========

WEIGHTED AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING
Basic 490,976 643,133
=========== ===========
Diluted 490,976 644,132
=========== ===========
</TABLE>

The accompanying notes are an integral part of the financial statements.

F-4
<PAGE> 22

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
STATEMENTS OF STOCKHOLDERS' (DEFICIENCY) EQUITY
YEARS ENDED DECEMBER 31, 1998 AND 1999

COMMON STOCK CAPITAL IN TOTAL
---------------------------- EXCESS OF ACCUMULATED STOCKHOLDERS
SHARES AMOUNT PAR VALUE DEFICIT EQUITY
----------- ----------- ----------- ----------- -----------

<S> <C> <C> <C> <C> <C>
BALANCE, JANUARY 1, 1998 478,164 $ 47,816 $ 1,193,004 $(1,240,812) $ 8

Exercise of common stock warrants 5,000 500 4,500 -- 5,000

Issuance of common stock
pursuant to note conversions 79,996 8,000 61,997 -- 69,997

Issuance of common stock for legal services 7,500 750 4,734 5,484

Issuance of common stock to officers and
directors 72,500 7,250 47,875 -- 55,125

Net (Loss) -- -- -- (229,445) (229,445)
----------- ----------- ----------- ----------- -----------

BALANCE, DECEMBER 31, 1998 643,160 64,316 1,312,110 (1,470,257) (93,831)

Repurchase of common stock (32) (3) (61) -- (64)

Net Income -- -- -- 522,437 522,437
----------- ----------- ----------- ----------- -----------

BALANCE, DECEMBER 31, 1999 643,128 $ 64,313 $ 1,312,049 $ (947,820) $ 428,542
=========== =========== =========== =========== ===========
</TABLE>

The accompanying notes are an integral part of the financial statements

F-5
<PAGE> 23

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1998 AND 1999

1998 1999

<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income $ (229,445) $ 522,437
Adjustments to reconcile net (loss) income
to net cash provided by operating activities
Stock issuance for services (Note 6) 60,609 --
Changes in assets and liabilities
Increase in accounts payable and accrued expenses 3,436 3,807
Discontinued Operations
Operating cash provided (used) 134,710 (50,267)
Gain on sale of discontinued segment -- (640,150)
Depreciation & amortization 60,047 7,929
----------- -----------

Net cash provided (used) by operating activities 29,357 (156,244)
----------- -----------

CASH FLOWS FROM INVESTING ACTIVITIES
Payments for patent costs (9,675) (6,190)
Cash used by discontinued operations (7,061) --
Net proceeds from sale of discontinued operations 8,150 802,673
----------- -----------

Net cash (used) provided by investing activities (8,586) 796,483
----------- -----------

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from officer loans 288,200 40,000
Payment of officer loans (198,370) (129,830)
Repayment of notes payable (40,000) (130,000)
Proceeds from short-term borrowings -- 29,000
Repayment of short-term borrowings (27,415) --
Proceeds from exercise of stock warrants 5,000 --
Cash paid for common stock -- (64)
Debt repayments by discontinued operations (40,036) (32,284)
----------- -----------

Net cash (used) by financing activities (12,621) (223,178)
----------- -----------

NET INCREASE IN CASH 8,150 417,061

CASH, BEGINNING OF YEAR -- 8,150
----------- -----------

CASH, END OF YEAR $ 8,150 $ 425,211
=========== ===========
</TABLE>

The accompanying notes are an integral part of the financial statements.

F-6
<PAGE> 24

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
STATEMENTS OF CASH FLOWS (CONTINUED)
YEARS ENDED DECEMBER 31, 1998 AND 1999

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

The Company paid cash for interest on short and long-term debt of $50,143 and
$9,705 during the years ended December 31, 1998 and 1999, respectively.

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

In 1998 the Company issued an aggregate 80,000 shares of common stock, valued at
$60,609 to officers and directors and to legal counsel for services rendered;
and issued 79,996 shares of common stock for conversion of notes payable.

The accompanying notes are an integral part of the financial statements.

F-7
<PAGE> 25

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION

Bio-Medical Automation, Inc. (formerly OZO Diversified Automation,
Inc.) (the Company) was incorporated under the laws of the State of
Colorado on October 13, 1983. The Company had been engaged in the
design, manufacture and marketing of robotic workstations for the
electronics industry, including routing and depaneling workstations
predominately to entities in North America and the Pacific Rim. In
November 1998 the Company entered into an Asset Purchase Agreement (the
"JOT Agreement") with JOT Automation, Inc. (JOT) a wholly owned Texas
subsidiary of JOT Automation Group OYJ, a Finnish corporation. Pursuant
to the agreement, the Company sold JOT all of its assets relating to
its depaneling and routing business in exchange for $920,000 and the
assumption of the operating liabilities related to the Company's
business assets. The sale was completed on March 9, 1999. Accordingly,
the Company's historical operations related to the assets sold to JOT
are considered to be "discontinued operations" for financial statement
purposes. (See Note 3.)

Subsequent to the sale to JOT, the Company's sole continuing operation
was the continuation of research and development activities on a
prototype micro-robotic device to manipulate organ tissues on an
extremely small scale. The Company has filed for a patent application
for the device. As of December 31, 1999 the Company's research and
development activities for the device were suspended, pending
assessment of the economic benefit of continuing research and
development activities or sale of the patent, as well as assessment of
other corporate opportunities.

RESEARCH AND DEVELOPMENT

Expenditures for the research and development of new products are
charged to operations as they are incurred.

INCOME TAXES

The Company has adopted the provisions of Statement of Financial
Accounting Standards (SFAS) No. 109, "Accounting for Income Taxes".
SFAS No. 109 requires recognition of deferred tax liabilities and
assets for the expected future tax consequences of events that have
been included in the financial statements or tax returns. Under this
method, the deferred tax liabilities and assets are determined based on
the difference between the financial statement and tax basis of assets
and liabilities using enacted tax rates in effect for the year in which
the differences are expected to reverse.

INCOME (LOSS) PER COMMON SHARE

Basic income (loss) per common share is calculated by dividing net
income (loss) by the weighted average number of common shares
outstanding during the year. Diluted income per common share is
calculated by adjusting outstanding shares, assuming conversion of all
potentially dilutive convertible equity instruments consisting of
warrants and options. Convertible equity instruments are not considered
in the calculation of loss per share for 1998, as their inclusion would
be antidilutive. There is no difference in the calculation of basic and
diluted income per share for 1999.

F-8
<PAGE> 26

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

CASH EQUIVALENTS

For purposes of reporting cash flows, the Company considers as cash
equivalents all highly liquid investments with a maturity of three
months or less at the time of purchase. On occasion, the company has
cash in banks in excess of federally insured amounts. At December 31,
1999 there were no cash equivalents.

USE OF ESTIMATES

The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and reported amounts of revenues and
expenses during the reporting period. Actual results could differ from
those estimates.

SHARE BASED COMPENSATION

In October 1995 SFAS No. 123, "Accounting for Stock-Based Compensation"
was issued. This new standard defines a fair value based method of
accounting for an employee stock option or similar equity instrument.
This statement gives entities a choice of recognizing related
compensation expense by adopting the new fair value method or to
continue to measure compensation using the intrinsic value approach
under Accounting Principles Board (APB) Opinion No. 25. The Company has
elected to utilize APB No. 25 for measurement; and will, pursuant to
SFAS No. 123, disclose supplementally the pro forma effects on net
income and earnings per share of using the new measurement criteria.
During the year ended December 31, 1998 the Company issued options to
purchase shares of its common stock.

PATENT COSTS

The Company has applied for a patent from the U.S. Patent Office for a
micro-robotic device under development. The costs associated with
obtaining this patent have been capitalized and will be initially
amortized over the life of the patent of seventeen years upon issuance
of the patent.

The patent is the Company's sole asset of continuing operations. In
1998 and 1999 the Company incurred research and development costs
associated with development of the micro-robotic device underlying the
patent and has, as of December 31, 1999, continued to assess the
economic benefit of continuing research and development activities or
sale of the patent.

In February 2000 the Company entered into an agreement with a
shareholder which, upon completion of the transaction, would result in
a change in control of the Company. (See Note 11.) The agreement
specifies that the Company owns certain intellectual property
consisting of the patent application and a related Technology License
Agreement.

Based on the foregoing, the Company has determined that the carrying
amount of the patent as of December 31, 1999 does not exceed its fair
value.

F-9
<PAGE> 27

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 1 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The Company has adopted SFAS No. 121, "Accounting for the Impairment of
Long-Lived Assets to be Disposed of", which requires that long-lived
assets to be held and used be reviewed for impairment whenever events
or changes in circumstances indicate that the carrying amount of an
asset may not be recoverable. The adoption of SFAS No. 121 has not had
an impact on the Company's financial statements, as the Company has
determined that no impairment loss for 1999 need to be recognized for
applicable assets of continuing operations. The recoverability of the
carrying value of patent costs will be evaluated on a recurring basis.

FAIR VALUE

The carrying amount reported in the balance sheet for cash, accounts
payable and accrued liabilities approximates fair value because of the
immediate or short-term maturity of these financial instruments.

CONCENTRATIONS OF CREDIT RISK

Financial instruments which potentially subject the Company to
concentrations of credit risk consist principally of cash. The Company
maintains cash accounts at two financial institutions. The Company
periodically evaluates the credit worthiness of these financial
institutions, and maintains cash accounts only in large high quality
financial institutions, thereby minimizing exposure for deposits in
excess of federally insured amounts. At December 31, 1999 cash in
excess of federally insured amounts was approximately $325,000.

NEW TECHNICAL PRONOUNCEMENTS

In June 1998 SFAS No. 133, "Accounting for Derivative Instruments and
Hedging Activities," was issued for fiscal years beginning after June
15, 1999. Adoption of SFAS No. 133 is not expected to have an impact on
the Company's financial statements.

In October 1998 SFAS No. 134, "Accounting for Mortgage Broker
Securities," was issued for fiscal years beginning after December 15,
1998. Adoption of SFAS No. 134 does not have an impact on the Company's
financial statements.

In February 1999 SFAS No. 135, "Rescission of FASB Statement No. 75 and
Technical Corrections" was issued for the fiscal years beginning after
February 15, 1999. Adoption of SFAS No. 135 is not expected to have an
impact on the Company's financial statements.

In June 1999 SFAS No. 136, "Transfers of Assets to a Not-For-Profit
Organization or Charitable Trust that Raises or Holds Contributions for
Others" was issued for fiscal years beginning after December 15, 1999.
Adoption of SFAS No. 136 is not expected to have an impact on the
Company's financial statements.

In June 1999 SFAS No. 137, "Accounting for Derivative Instruments and
Hedging Activities - Deferral of the Effective Date of FASB Statements
No. 133" was issued. Adoption of SFAS No. 137 is not expected to have
an impact on the Company's financial statements.

F-10
<PAGE> 28

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

The following significant accounting policies are attributable to
"discontinued operations:"

INVENTORIES

Inventories are stated at the lower of cost or market, with cost
determined on a first-in, first-out basis.

WARRANTY COSTS

The Company provides a warranty on products sold for a period of one
year from the date of sale. Estimated warranty costs are charged to
cost of sales at the time of sale.

PROPERTY AND EQUIPMENT

Property and equipment is stated at cost. Depreciation and amortization
of assets under capital lease is provided by use of the straight-line
method over the estimated useful lives of the related assets of three
to five years.

Expenditures for replacements, renewals and betterments are
capitalized. Maintenance and repairs are charged to operations as
incurred.

Depreciation expense and amortization of assets under capital lease of
discontinued operations was $51,921 and $7,929 for the years ended
December 31, 1998 and 1999, respectively.

NOTE 2 - BASIS OF ACCOUNTING

The accompanying financial statements have been prepared on the basis
of accounting principles applicable to a going concern which
contemplates the realization of assets and extinguishment of
liabilities in the normal course of business. As shown in the
accompanying financial statements, the Company has accumulated a
deficit of $947,820 through December 31, 1999. As discussed in Notes 1
and 3 the Company sold all of its assets relating to its historical
line of business and is concentrating its efforts in the research and
development of a micro-robotic device. There can be no assurance that
the Company will be able to conduct its operations to complete the
prototype micro-robotic device as contemplated. These factors indicate
that the Company may be unable to continue in existence. The Company's
financial statements do not include any adjustments related to the
carrying value of assets or the amount and classification of
liabilities that might be necessary should the Company be unable to
continue in existence. The Company's ability to establish itself as a
going concern is dependent on its ability to meet its financing and
cash requirements, to complete and successfully market its prototype
micro-robotic device, and ultimately to achieve profitable operations.
(See Note 11.)

F-11
<PAGE> 29

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 3 - DISCONTINUED OPERATIONS

As discussed in Note 1, in November 1998 the Company entered into the
JOT Agreement for the sale of all of its assets relating to its
depaneling and routing business. As part of the sale to JOT, JOT
licensed certain technology back to the Company, in addition to the
Company retaining the rights to a micro-robotic device. The
shareholders of the Company, on March 1, 1999, approved the sale to JOT
and approved the change of the Company's name to Bio-Medical
Automation, Inc. (BMA). The Company has accounted for the sale to JOT
of this reportable segment as discontinued operations.

The operating results of the segment sold have been reported separately
as discontinued operations in the accompanying statement of operations
and consists of the following:

1998 1999

<S> <C> <C>
Net sales $ 1,773,788 $ 525,465
Cost of sales 886,741 323,509
----------- -----------

Gross profit 887,047 201,956
----------- -----------
Operating expenses
General and administrative 367,208 72,810
Marketing and sales 454,353 75,615
Research and development 160,716 18,120
----------- -----------

982,277 166,545
----------- -----------
Other (expense) income
Interest expense (45,782) (2,372)
Other 990 --
----------- -----------

(44,792) (2,372)
----------- -----------

(Loss) income from discontinued operations $ (140,022) $ 33,039
=========== ===========

Gain on sale of discontinued segment $ -- $ 640,150
=========== ===========
</TABLE>

At December 31, 1998 the Company did not record any estimate for loss
on disposition of assets or any costs associated with the sale, as the
sale to JOT resulted in a gain to the Company which was realized in
1999.

In 1998 and 1999 the reporting segment sold to JOT comprised all
revenues generated by the Company. Revenues earned from customers
comprising more than 10% of total revenues for 1998 were $288,412 and
$297,821 representing 16% and 17%, respectively.

F-12
<PAGE> 30

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 3 - DISCONTINUED OPERATIONS (CONTINUED)

Revenues from sales of systems for 1998 and 1999 by geographic region
are as follows:

1998 1999

<S> <C> <C>
United States $ 880,903 $ 255,814
North America 114,587 --
Pacific Rim 48,000 --
Asia 49,000 --
South America 138,013 --
Other 70,780 --
</TABLE>

NOTE 4 - STOCKHOLDERS' EQUITY

COMMON STOCK

In 1998 the Company issued common stock as follows:

o 5,000 shares for exercise of a common stock warrant (issued in
1993) at a reduced exercise price of $1.00 per share.

o 79,996 shares for conversion of $70,000 face value of convertible
notes issued in 1993 at an exercise price reduced to $.875 per
share from $1.14 per share.

o 7,500 shares to an officer as additional compensation, valued at
$1.0125 per share.

o 65,000 shares to officers and directors (5 individuals), valued at
$.73125 per share.

In 1999 the company repurchased 32 shares of common stock from a
shareholder for $64 ($3.00 per share).

WARRANTS

At December 31, 1999 the Company had warrants outstanding to purchase
shares of the Company's common stock as follows:

o 100,000 shares at $1.00 per share, expiring April 1, 2001; issued
in 1996 in conjunction with short-term borrowings.

o 15,000 shares at $.75 per share, expiring October 1, 2001; issued
in conjunction with granting an extension on the due date of
short-term borrowings.

The weighted average exercise price of warrants outstanding at December
31, 1999 was $.97 per share.

F-13
<PAGE> 31

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 4 - STOCKHOLDERS' EQUITY (CONTINUED)

OPTIONS

The status of outstanding options granted by the Company is as follows:

NO. OF WEIGHTED AVG WEIGHTED AVG
SHARES EXERCISE PRICE FAIR VALUE

<S> <C> <C> <C>
Options Outstanding - January 1, 1998
(120,000 exercisable) 120,000 $ 1.13
======
Granted in 1998 25,000 $ 1.25 $ .36
------- ====== ======

Options Outstanding - December 31, 1998
(132,500 exercisable) 145,000 $ 1.15
======

Granted in 1999 -- --
======= ======

Options Outstanding - December 31, 1999
(145,000 exercisable) 145,000 $ 1.15
======= ======
</TABLE>

The Company has adopted the disclosure-only provisions of SFAS No. 123.
Had compensation cost for stock options issued in 1998, and vested in
1998 and 1999, been determined based on the fair value at the grant
date consistent with the provisions of SFAS No. 123, the Company's net
(loss) income and (loss) income per share for 1998 and 1999 would have
been as follows on a pro forma basis:

1998 1999
<S> <C> <C>
Net (loss) income applicable to common stockholders -
as reported $ (229,445) $ 522,437
----------- ---------
Net (loss) income applicable to common stockholders -
pro forma $ (233,977) $ 517,905
---------- ---------
(Loss) income per share basic and diluted - as reported $ (.47) $ .81
---------- ---------
(Loss) income per share basic and diluted - proforma $ (.48) $ .80
---------- ---------
</TABLE>

The fair value of each option grant is estimated on the date of grant
using the Black-Scholes option-pricing model with the following
weighted-average assumptions used for grants: dividend yield of 0%;
expected volatility of 15.83% to 43%; discount rate of 5.50% to 6.0%;
and expected lives of 5 years. No options were exercised or forfeited
during 1998 or 1999.

At December 31, 1999 the number of options exercisable was 145,000, the
weighted average exercise price of these options was $1.15, the
weighted average remaining contractual life of the options was 2.6
years and the exercise price was $1.13 to $1.25 per share.

NOTE 5 - INCOME TAXES

At December 31, 1999, the Company has net operating loss carryforwards
totaling approximately $421,000 that may be offset against future
taxable income through 2019 and research and development credits of
approximately $68,000 through 2013.

F-14
<PAGE> 32

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 5 - INCOME TAXES (CONTINUED)

The Company has fully reserved the tax benefits of these operating
losses and credits because the likelihood of realization of the tax
benefits cannot be determined. These carryforwards and credits are
subject to review by the Internal Revenue Service. The $63,000 tax
benefit of the loss carryforward and tax credits has been offset by a
valuation allowance of the same amount. The tax benefit of the loss
carry forward was reduced by $200,000 in 1999.

Temporary differences between the time of reporting certain items for
financial and tax reporting purposes, primarily from using different
methods of reporting depreciation costs and warranty and vacation
accruals, are not considered significant by management of the Company.

There is no current or deferred tax expense for the years ended
December 31, 1998 and 1999. The Company, in 1999, utilized net
operating loss carryforwards to offset taxable income, and, in 1998 had
no taxable income. The benefits of timing differences have not
previously been recorded.

A reconciliation between the statutory federal income tax rate (34%)
and the effective rate of income tax expense for 1999 is as follows:

<TABLE>

<S> <C>
Statutory federal income tax rate 31%
Increase (decrease) in taxes resulting from:
State tax, net of federal benefit 3
Utilization of net operating loss carryforwards (34)
-----
Effective Rate --%
=====
</TABLE>

NOTE 6 - RELATED PARTY TRANSACTIONS

In 1999 the former President of the Company made advances to the
Company of an aggregate $40,000. At completion of the sale to JOT the
former President and a director of the Company were repaid an aggregate
$129,380 of loans made to the company and $4,688 for interest due.

In 1999 the Company paid its former president/Director and its Chief
Financial Officer an aggregate $46,000 for services provided to the
Company subsequent to the sale to JOT in March 1999.

In 1998 the former President and a director loaned the Company an
aggregate $288,200, of which $198,370 and interest of $8,764 was repaid
during the year. At December 31, 1998, $89,830 and accrued interest of
$3,436 was due to the officer and to the director.

In November 1998, the Company issued to an officer 7,500 shares of
common stock, valued at $1.0125 per share as additional compensation.

In December 1998 the Board of Directors authorized the issuance of an
aggregate 65,000 shares of common stock and payment of $17,550 to
officers and directors as year end bonus.

F-15
<PAGE> 33

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 6 - RELATED PARTY TRANSACTIONS (CONTINUED)

In conjunction with the sale to JOT, the Company paid a "finders fee"
of 3.75% of the total consideration received to an entity controlled by
a former director of the Company. The payment was made pursuant to an
agreement entered into in June 1998.

NOTE 7 - SEGMENT REPORTING

In June 1997, SFAS No. 131, "Disclosure about Segments of an Enterprise
and Related Information" was issued, which amends the requirements for
a public enterprise to report financial and descriptive information
about its reportable operating segments. Operating segments, as defined
in the pronouncement, are components of an enterprise about which
separate financial information is available that is evaluated regularly
by the Company in deciding how to allocate resources and in assessing
performance. The financial information is required to be reported on
the basis that is used internally for evaluating segment performance
and deciding how to allocate resources to segments. The Company has
adopted SFAS No. 131 for the year ended December 31, 1998.

The Company has one reportable segment from continuing operations,
research and development of a micro-robotic device.

The Company has not earned any revenue from its research and
development activities. At December 31, 1999 assets of $18,724 are
attributable to this segment.

NOTE 8 - NET (LOSS) INCOME PER SHARE

The following represents a reconciliation from basic (loss) income per
share to diluted (loss) income per share:

1998 1999
---------- ----------
<S> <C> <C>
Determination of shares
Weighted average common shares outstanding 490,976 643,133
Assumed conversion of stock options -- 999
---------- ----------
Diluted shares outstanding 490,976 644,132
========== ==========

Basic (loss) income per common share $ (.47) $ .83
========== ==========
Diluted (loss) income per common share $ (.47) $ .83
========== ==========
</TABLE>

NOTE 9 - COMPREHENSIVE INCOME

There are no adjustments necessary to net (loss) income as presented in
the accompanying statements of operations to derive comprehensive
income in accordance with SFAS No. 130, "Reporting Comprehensive
Income".

NOTE 10 - RECLASSIFICATIONS

Certain amounts in the 1998 financial statements have been classified
to conform to 1999 classifications.

F-16
<PAGE> 34

BIO-MEDICAL AUTOMATION, INC.
(FORMERLY OZO DIVERSIFIED AUTOMATION, INC.)
NOTES TO FINANCIAL STATEMENTS

NOTE 11 - SUBSEQUENT EVENT

In February 2000 the Company entered into an agreement with a
shareholder wherein the Company agreed to cooperate and assist in the
shareholder acquiring shares of the Company's common stock from certain
individuals, who are also officers and/or directors of the Company,
under the terms and conditions set forth in the agreement. Upon
completion of the acquisition of the shares of common stock by the
purchasing shareholder, he would obtain control of the Company.

F-17
<PAGE> 35
ITEM 8. DISAGREEMENTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS

(a) IDENTIFICATION OF DIRECTORS AND EXECUTIVE OFFICERS. Currently the
following persons are the executive officers and directors of the Company. Each
person has submitted his resignation from the positions held, and it is expected
that this resignation will be effective shortly after this Form 10-KSB is filed,
not later than March 31, 2000.

NAME AND POSITION IN THE COMPANY AGE DIRECTOR SINCE
- -------------------------------- --- --------------

<S> <C> <C>
Alvin L. Katz 70 October 1996
(Chairman of the Board since October 1996, President
since November 1999)

David J. Wolenski 38 September 1996
(President from September 1996 through October 1999,
Director)

David W. Orthman 49 February 1992
(Director)

OFFICER SINCE
-------------
Brantley J. Halstead 42 February 1998
(Chief Financial Officer)
</TABLE>

Following the resignation of the foregoing persons on March 25,
2000, the following persons will become the executive officers and directors of
the Company:

NAME AND POSITION IN THE COMPANY AGE DIRECTOR SINCE
- -------------------------------- --- --------------

<S> <C> <C>
Steven N. Bronson, 34 March 2000
President, Secretary, Treasurer, and Chairman
of the Board

Leonard A. Hagen 48 March 2000
Director

Kenneth S. Schwartz 43 March 2000
Director
</TABLE>

17
<PAGE> 36

The present term of office of each director holding office will
expire at the next annual meeting of shareholders. The executive officers of the
Company are elected annually at the first meeting of the Company's Board of
Directors held after each Annual Meeting of Shareholders. Each executive officer
holds office until his successor is duly elected and qualified or until his
resignation or until he shall be removed in the manner provided by the Company's
Bylaws.

David J. Wolenski continued to serve as president of the Company,
and as a member of the Company's Board of Directors following the completion of
the JOT Transaction, until Mr. Wolenski resigned as president of BMA on November
1, 1999. After November 1, 1999, Mr. Wolenski has continued to serve as a
director of BMA until his resignation to be effective on March 25, 2000. After
November 1, 1999, Mr. Katz served as president until his resignation to be
effective on March 25, 2000.

Business Experience. The following is a brief account of the
business experience during the past five years of each director and executive
officer:

NAME OF DIRECTOR PRINCIPAL OCCUPATION DURING THE LAST FIVE YEARS

Alvin L. Katz Chairman of the Board since October 1996, President and
Chief Executive Officer since November 1999; Currently
serving on the Board of Directors of Amtech Systems,
Inc., a public company engaged in the manufacture of
capital equipment in the computer chip manufacturing
business; Blimpie International, a publicly held fast
food franchise; and Nastech Pharmaceutical Company,
Inc., a public company engaged in the development of
pharmaceuticals.

David J. Wolenski President and Chief Executive Officer from September
1996 through October 1999; Previously with Johns
Manville Corporation, a public company engaged in the
manufacture of fiberglass insulations and related
building materials, from July 1983 through July 1996;
Manufacturing manager at Johns Manville's Corona,
California facility, September 1994 through July 1996;
Manager of Quality Assurance for Johns Manville's
Performance Materials Division, March 1991 through
September 1994.

David W. Orthman Director of Research and Development since April 1,
1992; Director of Special Projects from June 6, 1990 to
March 31, 1992; Vice President of the Company from
January 1989 to June 1990; Chairman of the Board of
Directors of the Company from March 1988 to December
1988; President of the Company from October 1983 to
March 1988.

18
<PAGE> 37

Brantley J. Halstead Chief Financial Officer since February 1998; Corporate
Controller from September 1997 through January 1998;
independent Management Consultant from May 1993 to May
1995, and April 1996 through August 1997; Senior
Manager with Price Bednar Consulting LLC from June 1995
through March 1996; Management Consultant with Deloitte
& Touche from May 1988 through May 1993. The focus of
Mr. Halstead's management consulting efforts included
the use of information technology to facilitate
business process re-engineering. Currently Mr. Halstead
is employed as chief financial officer for Isonics
Corporation, a company with its common stock
registered under Section 12(g) of the Securities
Exchange Act of 1934, as amended.

Steven N. Bronson President, Secretary, Treasurer, and Chairman of the
Board of the Company as of March 25, 2000. Mr. Bronson
is the President of Catalyst Financial LLC, a
full-service securities brokerage and investment firm
and has held that position since September 24, 1998.
During the period of 1991 through September 23, 1998,
Mr. Bronson was President of Barber and Bronson,
Incorporated, a full-service securities brokerage
investment banking firm. Mr. Bronson has served as the
sole officer and director of Medtech Diagnostics, Inc.
a publicly traded corporation, since September, 1998
and Medtech's Chairman, President and Chief Executive
Officer during the period of June 1996 through
September 1998. In addition, Mr. Bronson is the
Chairman of Mikron Instrument company, Inc., a publicly
traded corporation.

Leonard Hagan Director of the Company as of March 25, 2000. For the
past seven years and currently, Mr. Hagan has worked as
a certified public accountant and is a partner at Hagan
& Burns CPA's, PC, in New York, New York. He received
his Bachelors of Arts degree in Economics from Ithaca
College in 1974, and earned his Masters of Business
Administration degree from Cornell University in 1976.

Kenneth Schwartz Director of the Company as of March 25, 2000. Dr.
Schwartz has been self-employed as a dentist in New
York, New York. Dr. Schwartz received his Bachelor of
Sciences from Brooklyn College in 1977 and earned his
D.D.S. from New York University College of Dentistry in
1982.

Directorships. Except as described above, no director of the
Company is a director of any other Company with a class of securities registered
pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, or
subject to the requirements of Section 15(d) of such Act, or any company
registered as an investment company under the Investment Company Act of 1940, as
amended.

19
<PAGE> 38

(b) IDENTIFICATION OF CERTAIN SIGNIFICANT EMPLOYEES.

N/A.

(c) FAMILY RELATIONSHIPS. As of December 31, 1999, and subsequently,
there were no family relationships between any director, executive officer, or
person nominated or chosen by the Company to become a director or executive
officer.

(d) INVOLVEMENT IN LEGAL PROCEEDINGS.

N/A.

(e) COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT. Section 16(a) of
the Securities Exchange Act of 1934 (the "1934 Act") requires the Company's
directors, executive officers and persons who own more than ten percent of a
registered class of the Company's equity securities, to file with the SEC
initial reports of ownership and reports to changes in ownership of Common Stock
and other equity securities of the Company. Officers and directors and greater
than ten percent shareholders are required by SEC regulation to furnish the
Company with copies of all Section 16(a) forms they file.

To the Company's knowledge, based solely on a review of the copies
of such reports furnished to the Company and written representations that no
other reports were required, and as of February 20, 2000, all Section 16(a)
filing requirements applicable to its officers, directors and greater than ten
percent beneficial owners were complied with.

20
<PAGE> 39

ITEM 10. EXECUTIVE COMPENSATION

Summary Compensation Table. The following table shows information
regarding compensation paid to the chief executive officers of BMA for the three
years ending December 31, 1999.

ANNUAL COMPENSATION LONG-TERM COMPENSATION
----------------------------------------- ----------------------
NAME AND OTHER ANNUAL RESTRICTED
PRINCIPAL POSITION YEAR SALARY BONUS COMPENSATION STOCK AWARDS OTHER
- ------------------ ---- ------ ----- ------------ ------------ -----

<S> <C> <C> <C> <C> <C> <C>
David J. Wolenski
CEO(1) 1999 $18,000 $ 0 $ 0 $ 0 None
CEO 1998 $48,000 $ 4,050 $ 0 $10,969 None
CEO 1997 $48,000 $ 0 $ 0 $18,750 None

Alvin L. Katz
CEO(2) 1999 $ 0 $ 0 $ 0 $ 0 None
</TABLE>

Note 1: David J. Wolenski resigned as CEO on November 1, 1999,
the salary shown is for the first ten months of the year.

Note 2: Alvin L. Katz became CEO on November 1, 1999. Mr. Katz
was paid no salary during 1999. Mr. Katz resigned this
position on March 25, 2000.

Other Plans. There are no other bonus, profit sharing, pension,
retirement, stock option, stock purchase, or other remuneration or incentive
plans in effect.

Long Term Incentive Plan. The Company has no long-term incentive
plans.

21
<PAGE> 40

Compensation of Directors. As of December 31, 1999, and for the
year then ended, cash compensation was not being paid to members of the Board of
Directors for their services as directors, except for their salaries as reported
above under executive officer compensation. On June 24, 1997, the Board granted
stock options to its directors in lieu of cash compensation, as described in
Note 6 of the Financial Statements. In summary, the Board granted 25,000 options
each to Alvin L. Katz and Scott E. Salpeter (a former director), and 35,000
options each to David W. Orthman and David J. Wolenski. All of the
aforementioned options were immediately vested as of the date of grant, and will
expire in five years on June 24, 2002. The exercise price is $1.125 per share
for the duration of the five-year option term.

On November 13, 1998, the Company awarded Brantley J. Halstead
15,000 shares of the Company's common stock valued at $7,593.

On December 30, 1998, the Compensation Committee of the Board of
Directors made stock and cash bonus awards to David J. Wolenski ($10,969 in the
Company's common stock and $4,050 in cash); David W. Orthman ($10,969 in the
Company's common stock and $4,050 in cash); Brantley J. Halstead ($10,969 in the
Company's common stock and $4,050 in cash); Alvin L. Katz ($10,969 in the
Company's common stock and $4,050 in cash); and Scott E. Salpeter ($3,656 in the
Company's common stock and $1,350 in cash).

Employment Contracts and Termination of Employment and
Change-in-Control Arrangements. As of December 31, 1999, the Company had no
formalized employment contracts with any executive officer. The Company has no
compensation plan or arrangement with respect to any executive officer which
plan or arrangement results or will result from the resignation, retirement or
any other termination of such individual's employment with the Company. The
Company has no plan or arrangement with respect to any such persons, which will
result from a change in control of the Company or a change in the individual's
responsibilities following a change in control.

22
<PAGE> 41

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Security Ownership of Management. The following table sets forth, as of
March 25, 2000, the number of shares of the Company's Common Stock beneficially
owned by owner's of more than five percent of the Company's outstanding Common
Stock who are known to the Company and the Directors of the Company,
individually, and the Officers and Directors of the Company as a group, and the
percentage of ownership of the outstanding Common Stock represented by such
shares.

AMOUNT AND NATURE OF PERCENT
NAME OF BENEFICIAL OWNER POSITION WITH COMPANY BENEFICIAL OWNERSHIP OF CLASS
- ------------------------ --------------------- -------------------- --------

<S> <C> <C> <C>
David W. Orthman Director 0(1) 0.0%
303 East 17th Ave, Suite 780
Denver, Colorado 80203

David J. Wolenski Director throughout 1999; 0(2) 0.0%
303 East 17th Ave, Suite 780 President and Chief Executive
Denver, Colorado 80203 Officer (until November 1, 1999)

Brantley J. Halstead Chief Financial Officer 0(3) 0.0%
303 East 17th Ave, Suite 780
Denver, Colorado 80203

Alvin L. Katz Director, Chairman, throughout 0(4) 0.0%
303 East 17th Ave, Suite 780 1999, President and Chief
Denver, Colorado 80203 Executive Officer (effective
November 1, 1999)

All Officers and Directors 0 0.0%
as a Group (4 Persons)

Steven N. Bronson Chairman, President, and Chief 512,647(5) 62.5%
900 3rd Ave., Suite 201 Executive Officer (effective
New York, NY 10022 March 25, 2000)

Dr. Kenneth S. Schwartz Director (effective March 25, 17,500(6) 1%
2000)
</TABLE>

23
<PAGE> 42

Note (1): Mr. Orthman, with his wife, sold all of his shares and options
to purchase shares of the Company's common stock to Mr.
Bronson in March 2000 for total consideration of $118,695.50.

Note (2): Mr. Wolenski sold all of his shares and options to purchase
shares of the Company's common stock to Mr. Bronson in March
2000 for total consideration of $51,800.

Note (3): Mr. Halstead sold all of his shares and options to purchase
shares of the Company's common stock to Mr. Bronson in March
2000 for total consideration of $26,125.

Note (4): Mr. Katz, his wife, and a private investment partnership
affiliate of Mr. Katz, sold all shares and options to purchase
shares of the Company's common stock to Mr. Bronson in March
2000 for total consideration of $73,623.20.

Note (5): Includes direct and indirect beneficial ownership, and
includes 177,500 representing currently exercisable warrants
or options to purchase common stock.

Note (6): These shares are owned by Dr. Schwartz's wife. Dr. Schwartz
disclaims beneficial ownership of these shares.

As a result of the transaction with Mr. Bronson described
above, the Company mailed to its shareholders on March 5,
2000, a notification pursuant to Rule 14f-1 regarding a change
of control of the Company.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

There are no material relationships between the Company and
the current officers and directors or any of the persons expected to become
directors or executive officers of the Company other than those transactions
described below:

Corporate Loans. During the fiscal year ended December 31,
1998 and 1999 certain related parties advanced loans to the Company as follows:

After December 31, 1997, Alvin L. Katz, then a director of the
Company, advanced funds to the Company for working capital purposes. The Company
issued an interest bearing (at 10%) promissory note in the amount of $75,000,
which was secured by substantially all of the Company's assets. Mr. Katz's loan
to the Company was originally repayable on December 30, 1998, but was extended
by Mr. Katz for no additional consideration until February 28, 1999. The Company
repaid this loan in February 1999.

Subsequent to December 31, 1997, Mr. Wolenski loaned the
Company an additional $213,200, for working capital purposes. This amount bore
interest at 2% over prime. The Company repaid this amount in February 1999.

24
<PAGE> 43

Transaction With CapitaLink. The Company entered into an
investment banking agreement in June 1998 with Catalyst Financial Corp. of
Miami, Florida ("Catalyst"). At the time the Company entered into the agreement
with Catalyst, Steven Bronson who owned more than 10% of the Company's
outstanding stock, was also affiliated with Catalyst. It was the Company's
intention to use Catalyst as its primary advisor in its efforts to facilitate
its restructuring. Catalyst assigned this contract to CapitaLink in early 1999.
Mr. Bronson had no interest in CapitaLink. The Company paid CapitaLink
approximately $40,000 as consideration for assisting in the sale of the
Company's assets to JOT Automation, Inc. ("JOT") in March 1999. As a result of
the completion of the transaction with JOT, the agreement expired.

Change in Control. In a transaction described in "Recent
Transactions and Change In Control," the following persons sold the following
securities to Steven Bronson pursuant to the Purchase Agreement. The following
table sets forth information regarding the private transaction recently
completed between certain officers and directors of the Company who sold shares,
options, and warrants to Mr. Bronson:

$0.75 $1.00 TOTAL
WARRANTS WARRANTS $1.125 $1.25 CONSIDERATION
NAME SHARES (a) (b) OPTIONS(c) OPTIONS(d) RECEIVED
---- ------ -------- -------- ---------- ---------- ------------

<S> <C> <C> <C> <C> <C> <C>
Alvin L. Katz and
affiliates 64,284 3,750 25,000 25,000 0 $ 73,623.20

David W. Orthman
and wife 109,710 0 0 35,000 0 $118,695.50

David J. Wolenski 46,000 0 0 35,000 0 $ 51,800.00

Brantley J.
Halstead 22,500 0 0 0 25,000 $ 26,125.00
</TABLE>

Note (a) Exercisable through October 10, 2001.

Note (b) Exercisable through April 1, 2001.

Note (c) Exercisable through June 24, 2002.

Note (d) Exercisable through February 16, 2003.

Indebtedness of Management. There is no indebtedness nor has there
been any indebtedness of management to the Company in excess of $60,000 since
the last fiscal year beginning January 1, 1999.

25
<PAGE> 44

ITEM 13. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K

(a) FINANCIAL STATEMENTS:

Independent Auditors' Report

Balance Sheet--As of December 31, 1999

Statements of Operations--Years Ended December 31, 1998, and 1999

Statements of Stockholders' Equity--Years Ended December 31, 1998,
and 1999

Statements of Cash Flows for the Years Ended December 31, 1998,
and 1999

Notes to Financial Statements

(b) 8-K REPORTS:

No reports on Form 8-K have been filed since December 31, 1999.

During 1999 one report on Form 8-K reporting an event of March 9, 1999
under Items 2 and 5--the completion of the JOT Transaction, the Company's name
change, and an amendment to the Company's articles of incorporation--was filed.

3.1 Articles of Incorporation, incorporated by reference to
Registration Statement No. 33-13074-D as Exhibit 3.1

3.2 Amended Bylaws adopted June 1, 1987, incorporated by reference
to Annual Report on Form 10-K for the fiscal year ended
December 31, 1987 as Exhibit 3.2.

3.4 Articles of Amendment to Restated Articles of Incorporation
dated March 7, 1991. Incorporated by reference to Annual
Report on Form 10-K for fiscal year ended December 31, 1990 as
Exhibit 3.4.

3.5 Articles of Amendment to Restated Articles of Incorporation
dated March 17, 1999, incorporated by reference to Form 8-K
reporting an event of March 9, 1999.

10.1 OEM Purchase Agreement dated January 15, 1990, between the
Company and Ariel Electronics, Inc. incorporated by reference
to Annual Report on Form 10-K for the fiscal year ended
December 31, 1989 as Exhibit 10.16.

10.2 Form of Convertible Promissory Note, 12/30/93 Private
Placement incorporated by reference to Annual Report on Form
10-KSB for the fiscal year ended December 31, 1993 as Exhibit
10.2.

26
<PAGE> 45

10.3 Form of Non-Convertible Promissory Note, 12/30/93 Private
Placement incorporated by reference to Annual Report on Form
10-KSB for the fiscal year ended December 31, 1993 as Exhibit
10.3.

10.4 Form of Note Purchaser Warrant Agreement and Warrant, 12/30/93
Private Placement incorporated by reference to Annual Report
on Form 10-KSB for the fiscal year ended December 31, 1993 as
Exhibit 10.4.

10.5 Form of Promissory Note, 4/1/96.

10.6 Form of Security Agreement, 4/1/96.

10.7 Form of Common Stock Purchase Warrant, 4/1/96.

10.8 Form of Promissory Note, 7/1/96.

10.9 Form of 4/1/96 Promissory Note Extension, 10/17/96.

10.10 Form of Common Stock Purchase Warrant, 10/10/96.

10.11 Asset Purchase Agreement with JOT incorporated by reference to
Form 8-K reporting an event of November 4, 1998, and amendment
thereto incorporated by reference to Form 8-K reporting an
event of December 15, 1998

27 Financial Data Schedule

27
<PAGE> 46

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

Dated: March 24, 1999

BIO-MEDICAL AUTOMATION, INC.,
a Colorado corporation

By: /s/ Alvin L. Katz
-------------------------------------------
Alvin L. Katz
President and CEO

Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the Registrant and in the capacities and on the dates indicated:

Date Name and Title Signature

<S> <C> <C>
March 24, 2000 David J. Wolenski /s/ David J. Wolenski
Former Principal Executive Officer ------------------------------
Former Principal Financial Officer
Former Director

March 24, 2000 David W. Orthman /s/ David W. Orthman
Former Director ------------------------------

March 24, 2000 Alvin L. Katz /s/ Alvin L. Katz
Former Chairman of the Board -----------------------------
Former Principal Executive Officer
Former Principal Financial Officer

March 24, 2000 Brantley J. Halstead /s/ Brantley J. Halstead
Former Principal Accounting Officer ----------------------------
Former Chief Financial Officer
</TABLE>

28
<PAGE> 47

EXHIBIT INDEX

EXHIBIT
NUMBER DESCRIPTION
------- -----------

<S> <C>
3.1 Articles of Incorporation, incorporated by reference to
Registration Statement No. 33-13074-D as Exhibit 3.1

3.2 Amended Bylaws adopted June 1, 1987, incorporated by reference
to Annual Report on Form 10-K for the fiscal year ended
December 31, 1987 as Exhibit 3.2.

3.4 Articles of Amendment to Restated Articles of Incorporation
dated March 7, 1991. Incorporated by reference to Annual
Report on Form 10-K for fiscal year ended December 31, 1990 as
Exhibit 3.4.

3.5 Articles of Amendment to Restated Articles of Incorporation
dated March 17, 1999, incorporated by reference to Form 8-K
reporting an event of March 9, 1999.

10.2 Form of Convertible Promissory Note, 12/30/93 Private
Placement incorporated by reference to Annual Report on Form
10-KSB for the fiscal year ended December 31, 1993 as Exhibit
10.2.
</TABLE>

29
<PAGE> 48

<TABLE>

<S> <C>
10.3 Form of Non-Convertible Promissory Note, 12/30/93 Private
Placement incorporated by reference to Annual Report on Form
10-KSB for the fiscal year ended December 31, 1993 as Exhibit
10.3.

10.5 Form of Promissory Note, 4/1/96.

10.6 Form of Security Agreement, 4/1/96.

10.7 Form of Common Stock Purchase Warrant, 4/1/96.

10.8 Form of Promissory Note, 7/1/96.

10.9 Form of 4/1/96 Promissory Note Extension, 10/17/96.

10.10 Form of Common Stock Purchase Warrant, 10/10/96.

27 Financial Data Schedule
</TABLE>

<ARTICLE> 5

<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> DEC-31-1999
<CASH> 425,211
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 425,211
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 443,935
<CURRENT-LIABILITIES> 15,393
<BONDS> 0
0
0
<COMMON> 64,313
<OTHER-SE> 364,229
<TOTAL-LIABILITY-AND-EQUITY> 443,935
<SALES> 0
<TOTAL-REVENUES> 13,132
<CGS> 0
<TOTAL-COSTS> 163,884
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 4,014
<INCOME-PRETAX> (150,752)
<INCOME-TAX> 0
<INCOME-CONTINUING> (150,752)
<DISCONTINUED> 673,189
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 522,437
<EPS-BASIC> .81
<EPS-DILUTED> .81

</TABLE>